3,116 enterprises
The EU had 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations) in 2023.
Eurostat428.65 EUR billion
EU enterprises in NACE class C2120 had net turnover of €428.65 billion in 2023.
EurostatWhy this market is moving now
- US employment in the core industry shifted -2% since 2020.
- Clinical research is active, with studies recruiting now.
What this market covers
Laboratory tests that detect inherited blood disorders such as sickle cell disease and thalassemia in adults. They guide treatment, family planning and transfusion decisions.
Typical segments
- Hemoglobin electrophoresis
- High performance liquid chromatography
- Genetic testing
- Point of care sickle tests
Who buys
- Clinical laboratories
- Hospitals
- Hematology clinics
Key figures
Each figure links to the page it came from.
| Figure | Value | Year | Source |
|---|---|---|---|
| The EU had 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations) in 2023. | 3,116 enterprises | 2023 | Eurostat |
| EU enterprises in NACE class C2120 had net turnover of €428.65 billion in 2023. | 428.65 EUR billion | 2023 | Eurostat |
| NACE class C2120 employed 600,730 people across the EU in 2023. | 600,730 persons employed | 2023 | Eurostat |
| The US had 500 private establishments in NAICS 325413 (In-vitro diagnostic substance manufacturing) in 2025. | 500 establishments | 2025 | U.S. Bureau of Labor Statistics |
| NAICS 325413 employed an average of 28,101 people in US private industry in 2025. | 28,101 jobs | 2025 | U.S. Bureau of Labor Statistics |
| US employment in NAICS 325413 changed by -2% between 2020 (28,792 jobs) and 2025, calculated from BLS figures. | -2 % change | 2025 | U.S. Bureau of Labor Statistics |
| Average annual pay in US NAICS 325413 was $118,381 in 2025. | 118,381 USD per year | 2025 | U.S. Bureau of Labor Statistics |
| ClinicalTrials.gov lists 1,217 registered studies for the condition "sickle cell disease". | 1,217 registered studies | 2026 | U.S. National Library of Medicine (ClinicalTrials.gov) |
| 165 of those studies were recruiting participants when checked in November 2026. | 165 recruiting studies | 2026 | U.S. National Library of Medicine (ClinicalTrials.gov) |
What the full report covers
- 1
Executive summary
The answer on two pages: size, growth and what drives it.
- 2
Market size and outlook
History, the current year and a five-year view with base, low and high cases.
- 3
Segments and regions
Splits by product, buyer and geography across the US, Europe and MEA.
- 4
Company profiles
The main players, how they compete and where they are investing.
- 5
Data and method
Every figure in Excel, with the sources and assumptions behind it.
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the United States market - 03Market size, 2021 to 2025
Historical series and growth rates - 04Outlook to 2031
Base, low and high scenarios with stated assumptions - 05Rules, policy and deadlines
Regulation and programmes that change demand - 06Drivers and barriers
What accelerates or slows adoption, by customer segment - 07Prices, costs and margins
Unit economics where public data allows - 08Competitive landscape
8 to 12 company profiles with recent moves - 09Opportunities and risks
For new entrants, suppliers and investors - 10Method and sources
Every assumption and source, listed
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How many clinical trials study sickle cell disease?
ClinicalTrials.gov lists 1,217 registered studies.
How many US companies are in the adult hemoglobinopathy testing industry?
BLS counts 500 private establishments in NAICS 325413 (In-vitro diagnostic substance manufacturing), the closest official industry.
How many EU companies are in the adult hemoglobinopathy testing industry?
Eurostat counts 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations).
Sources and method
The figures on this page come from the public sources listed below. Read how we work.
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs ENT_NR, 2023, 3116
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs NETTUR_MEUR, 2023, 428651
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs EMP_NR, 2023, 600730
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325413, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325413, annual_avg_estabs 500
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325413, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325413, annual_avg_emplvl 28101
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325413, 2025 (2026-11-04)
QCEW 2020 annual_avg_emplvl 28792; 2025 annual_avg_emplvl 28101
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325413, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325413, avg_annual_pay 118381
- U.S. National Library of Medicine (ClinicalTrials.gov): ClinicalTrials.gov API v2, condition "sickle cell disease" (2026-11-04)
query.cond=sickle cell disease totalCount 1217
- U.S. National Library of Medicine (ClinicalTrials.gov): ClinicalTrials.gov API v2, condition "sickle cell disease", status recruiting (2026-11-04)
filter.overallStatus=RECRUITING totalCount 165
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. You owe us nothing for asking.
- Full table of contents
- Two sample chapters
- Method note and data outline